Results 41 to 50 of about 19,009 (196)
Gender effects on cytidine analogue metabolism and myelodysplastic syndrome treatment outcomes [PDF]
In vivo, half-lives of cytidine analogues such as 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), are determined largely by cytidine deaminase (CDA), an enzyme that rapidly metabolizes these drugs into inactive uridine ...
Joseph Covey +13 more
core
Introduction. The incidence of Acute Myeloid Leukemia (AML) increases progressively with age and its treatment is challenging. This prospective case control study was undertaken to compare the safety, efficacy, and cost-effectiveness of decitabine with ...
Linu A. Jacob +6 more
doaj +1 more source
Dysregulation of DNA methylation is an established feature of breast cancers. DNA demethylating therapies like decitabine are proposed for the treatment of triple-negative breast cancers (TNBC) and indicators of response need to be identified.
Maillet, Hillary +12 more
core +3 more sources
In vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia [PDF]
Decitabine is a hydrophilic drug that acts by hypomethylating DNA and is used in Europe for the treatment of acute myeloid leukemia (AML) in older patients. However, it can only be administered intravenously, due to very low oral bioavailability.
Verger, Alexis +5 more
core +2 more sources
Background Methylation-mediated silencing of genes is one epigenetic mechanism implicated in cancer. Studies regarding the role of modulation of gene expression utilizing inhibitors of DNA methylation, such as decitabine, in osteosarcoma (OS) have been ...
Xue Hui +9 more
doaj +1 more source
This work develops a metabolic sharing strategy that employs cytidine monophosphate (CMP) to competitively reprogram floxuridine (FUDR) pyrimidine metabolism in colorectal tumor cells. Elevated intracellular FdUMP induces nucleotide imbalance, drives mitochondrial DNA release and cGAS‐STING innate immune cascade activation, and potentiates robust ...
Chao Wang +10 more
wiley +1 more source
Objective Combination therapy has become the hallmark of lung cancer treatment, as it reduces the dosage intensity of individual drugs while increasing their efficacy.
Maoyi Xu +3 more
doaj +1 more source
This Review outlines the biological framework of entry, maintenance, and awakening in dormant minimal residual disease across gynecologic cancers. By mapping critical biological dependencies—from metabolic plasticity to microenvironment interactions—it evaluates novel interception concepts and presents a translational framework combining single‐cell ...
Shih‐Hsuan Cheng +7 more
wiley +1 more source
Total DNA methylation in the brain in response to decitabine treatment in female rats
Hypomethylating agent decitabine is being used in the treatment of certain types of leukaemia in combination with other anticancer drugs. Aberrant DNA methylation has been suggested to occur in pathological states including depression.
Balagova L. +3 more
doaj +1 more source
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. [PDF]
Decitabine, an epigenetic modifier that reactivates genes otherwise suppressed by DNA promoter methylation, is effective for some, but not all cancer patients, especially those with solid tumors.
Ruth Halaban +15 more
doaj +1 more source

